Health Care & Life Sciences » Pharmaceuticals | Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
709
811
804
668
1,023
2,085
Total Accounts Receivable
11
4
11
108
63
13
Inventories
8
6
7
7
10
9
Other Current Assets
8
16
15
15
72
101
Total Current Assets
736
837
837
798
1,168
2,208
Net Property, Plant & Equipment
86
89
90
93
122
132
Intangible Assets
20
20
19
20
22
24
Other Assets
5
10
1
1
10
13
Total Assets
847
956
948
912
1,322
2,668
ST Debt & Current Portion LT Debt
4
3
9
1
2
Accounts Payable
11
18
28
21
25
Other Current Liabilities
82
94
111
111
198
Total Current Liabilities
98
115
149
134
225
Long-Term Debt
228
455
464
588
606
Other Liabilities
143
128
134
91
73
Total Liabilities
469
698
747
813
903
Common Equity (Total)
378
258
201
100
331
Total Shareholders' Equity
378
258
201
100
331
Total Equity
378
258
201
100
419
Liabilities & Shareholders' Equity
847
956
948
912
1,322
Accumulated Minority Interest
-
-
-
-
88

About Ionis Pharmaceuticals

View Profile
Address
2855 Gazelle Court
Carlsbad California 92010
United States
Employees -
Website http://www.ionispharm.com
Updated 07/08/2019
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs.